The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available data is limited with heterogeneous patient cohorts,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2022.1039121/full |
| _version_ | 1828288992210059264 |
|---|---|
| author | Deniz Can Guven Taha Koray Sahin Enes Erul Alessandro Rizzo Angela Dalia Ricci Sercan Aksoy Suayib Yalcin |
| author_facet | Deniz Can Guven Taha Koray Sahin Enes Erul Alessandro Rizzo Angela Dalia Ricci Sercan Aksoy Suayib Yalcin |
| author_sort | Deniz Can Guven |
| collection | DOAJ |
| description | Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available data is limited with heterogeneous patient cohorts, sample sizes and variable cut-offs. Therefore, we conducted a systematic review and meta-analysis to evaluate the association between survival outcomes and albumin levels in patients treated with ICIs.Methods: We conducted a systematic review using the PubMed, Web of Science, and Embase databases to filter the published studies up to 1 June 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model due to the high degree of heterogeneity. The primary outcome measure was hazard ratio (HR) with 95% confidence intervals (CI). The study protocol was registered with the PROSPERO registry (Registration Number: CRD42022337746).Results: Thirty-six studies encompassing 8406 cancer patients with advanced disease were included in the meta-analyses. Almost half of the studies were conducted in NSCLC cohorts (n = 15), and 3.5 gr/dL was the most frequently used albumin cut-off in the included studies (n = 20). Patients with lower albumin levels had a significantly increased risk of death (HR: 1.65, 95% CI: 1.52–1.80, p < 0.0001) than patients with higher albumin levels. Subgroup analyses for study location, sample size, tumor type and albumin cut-off were demonstrated consistent results. Furthermore, in the subgroup analysis of eight studies using albumin levels as a continuous prognostic factor, every 1 gr/dL decrease in albumin levels was associated with significantly increased risk of death by a factor of 10% (HR: 1.10, 95% CI: 1.05–1.16, p = 0.0002). Similar to analyses with overall survival, the patients with lower albumin levels had an increased risk of progression or death compared to patients with higher albumin levels (HR: 1.76, 95% CI: 1.40–2.21, p < 0.001).Conclusion: The available evidence demonstrates that albumin levels may be a prognostic biomarker in advanced cancer patients treated with ICIs. Further research is needed to delineate the role of albumin levels in patients treated with ICIs in the adjuvant setting, as well as the possible benefit of therapeutic approaches to improve hypoalbuminemia. |
| first_indexed | 2024-04-13T10:13:52Z |
| format | Article |
| id | doaj.art-3ae9093ba7964ef68f6b39871f995827 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-04-13T10:13:52Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-3ae9093ba7964ef68f6b39871f9958272022-12-22T02:50:48ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2022-12-01910.3389/fmolb.2022.10391211039121The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysisDeniz Can Guven0Taha Koray Sahin1Enes Erul2Alessandro Rizzo3Angela Dalia Ricci4Sercan Aksoy5Suayib Yalcin6Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDepartment of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, TurkeyDepartment of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, TurkeyStruttura Semplice Dipartimentale di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello”, Bari, ItalyMedical Oncology Unit, National Institute of Gastroenterology, “Saverio de Bellis” Research Hospital, Castellana Grotte, ItalyDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyBackground: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available data is limited with heterogeneous patient cohorts, sample sizes and variable cut-offs. Therefore, we conducted a systematic review and meta-analysis to evaluate the association between survival outcomes and albumin levels in patients treated with ICIs.Methods: We conducted a systematic review using the PubMed, Web of Science, and Embase databases to filter the published studies up to 1 June 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model due to the high degree of heterogeneity. The primary outcome measure was hazard ratio (HR) with 95% confidence intervals (CI). The study protocol was registered with the PROSPERO registry (Registration Number: CRD42022337746).Results: Thirty-six studies encompassing 8406 cancer patients with advanced disease were included in the meta-analyses. Almost half of the studies were conducted in NSCLC cohorts (n = 15), and 3.5 gr/dL was the most frequently used albumin cut-off in the included studies (n = 20). Patients with lower albumin levels had a significantly increased risk of death (HR: 1.65, 95% CI: 1.52–1.80, p < 0.0001) than patients with higher albumin levels. Subgroup analyses for study location, sample size, tumor type and albumin cut-off were demonstrated consistent results. Furthermore, in the subgroup analysis of eight studies using albumin levels as a continuous prognostic factor, every 1 gr/dL decrease in albumin levels was associated with significantly increased risk of death by a factor of 10% (HR: 1.10, 95% CI: 1.05–1.16, p = 0.0002). Similar to analyses with overall survival, the patients with lower albumin levels had an increased risk of progression or death compared to patients with higher albumin levels (HR: 1.76, 95% CI: 1.40–2.21, p < 0.001).Conclusion: The available evidence demonstrates that albumin levels may be a prognostic biomarker in advanced cancer patients treated with ICIs. Further research is needed to delineate the role of albumin levels in patients treated with ICIs in the adjuvant setting, as well as the possible benefit of therapeutic approaches to improve hypoalbuminemia.https://www.frontiersin.org/articles/10.3389/fmolb.2022.1039121/fullbiomarkercancerimmunotherapyprognosisalbumin |
| spellingShingle | Deniz Can Guven Taha Koray Sahin Enes Erul Alessandro Rizzo Angela Dalia Ricci Sercan Aksoy Suayib Yalcin The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis Frontiers in Molecular Biosciences biomarker cancer immunotherapy prognosis albumin |
| title | The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
| title_full | The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
| title_fullStr | The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
| title_full_unstemmed | The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
| title_short | The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
| title_sort | association between albumin levels and survival in patients treated with immune checkpoint inhibitors a systematic review and meta analysis |
| topic | biomarker cancer immunotherapy prognosis albumin |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2022.1039121/full |
| work_keys_str_mv | AT denizcanguven theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT tahakoraysahin theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT eneserul theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT alessandrorizzo theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT angeladaliaricci theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT sercanaksoy theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT suayibyalcin theassociationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT denizcanguven associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT tahakoraysahin associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT eneserul associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT alessandrorizzo associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT angeladaliaricci associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT sercanaksoy associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT suayibyalcin associationbetweenalbuminlevelsandsurvivalinpatientstreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis |